More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests SOUTH SAN FRANCISCO, ...

MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of PROSTOX™ Standard, a new, clinically validated genetic ...

Men could soon be offered quick MRI scans lasting under 15 minutes to detect prostate cancer earlier, under new ...

Urologists, radiologists and pathologists from Europe and the US agreed an “expert consensus statement” on prostate cancer treatment and diagnosis ...

Prostate cancer screening saves many more lives than earlier studies suggested, research shows. The results from the longest-running European trial show one life saved for every six men diagnosed, a ...

Prostate cancer is one of the most common cancers affecting men around the world. It develops in the prostate, a small gland ...

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today more than 15 abstracts featuring its urology portfolio will be presented at the 2026 ASCO Genitourinary Cancers ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

Researchers found men who ejaculated more often had fewer prostate cancer diagnoses, pointing to a possible biological ...

While many people are familiar with mammograms and smear tests, prostate screening is talked about far less. Ahead of Prostate Cancer Awareness Month in March, Mr Wissam Abou-Chedid, consultant ...